FRNM
Freenome, Inc. Common stock
Price Chart
Latest Quote
$13.14
+0.13 (+1.00%)
Current Price
| Previous Close | $13.01 |
| Open | $13.00 |
| Day High | $13.86 |
| Day Low | $12.25 |
| Volume | 704,145 |
Stock Information
| Shares Outstanding | 106.10M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $1.39B |
| EPS (TTM) | $-2.14 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $11.43 |
| SMA50 | $11.28 |
| SMA200 | $11.72 |
| RSI | 77.01 |
| ATR | 0.8141 |
| Rel Volume | 2.38 |
Performance History
| Week | +10.70% |
| Month | +19.35% |
| Quarter | +16.28% |
| 6 Months | -3.03% |
| YTD | +1.08% |
| Year | +23.96% |
| 10 Years | +30.75% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-22 | $13.14 | 705,900 |
| 2026-07-21 | $13.01 | 577,800 |
| 2026-07-20 | $11.95 | 109,100 |
| 2026-07-17 | $11.90 | 40,000 |
| 2026-07-16 | $12.00 | 148,700 |
| 2026-07-15 | $11.87 | 76,500 |
| 2026-07-14 | $11.85 | 221,700 |
| 2026-07-13 | $10.98 | 461,400 |
| 2026-07-10 | $10.80 | 187,200 |
| 2026-07-09 | $10.90 | 506,400 |
| 2026-07-08 | $11.40 | 55,500 |
| 2026-07-07 | $11.50 | 734,400 |
| 2026-07-06 | $10.83 | 719,000 |
| 2026-07-02 | $11.00 | 241,000 |
| 2026-07-01 | $10.86 | 132,100 |
| 2026-06-30 | $10.88 | 99,900 |
| 2026-06-29 | $10.92 | 296,000 |
| 2026-06-26 | $10.93 | 250,400 |
| 2026-06-25 | $10.96 | 279,300 |
| 2026-06-24 | $11.02 | 91,100 |
| 2026-06-23 | $10.91 | 116,100 |
About Freenome, Inc. Common stock
Freenome Holdings, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based tests for early cancer detection, including a test for colorectal cancer screening. It offers a multiomics platform that combines computational biology, machine learning, and multiple data types to identify biomarkers and detect various cancers. The company conducts clinical research programs, such as the PREEMPT CRC, Sanderson, and Vallania studies, to validate and expand its cancer detection tests to multiple cancer types. It collaborates with healthcare organizations and partners to advance clinical studies and enhance its product portfolio, including an autoantibody platform with additional biomarkers, and provides patient stratification and monitoring solutions using its multiomics technology. The company was founded in 2014 and is based in Brisbane, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on FRNM.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Reconciled Cost Of Revenue | $1,944,000 | $2,564,000 |
| Cost Of Revenue | $1,944,000 | $2,564,000 |
| Total Revenue | $30,409,000 | $2,882,000 |
| Operating Revenue | $30,409,000 | $2,882,000 |
| Expenses | ||
| Interest Expense | $2,820,000 | $0 |
| Total Expenses | $253,878,000 | $294,855,000 |
| Other Income Expense | $32,000 | $-32,000 |
| Other Non Operating Income Expenses | $32,000 | $-32,000 |
| Net Non Operating Interest Income Expense | $4,094,000 | $17,584,000 |
| Interest Expense Non Operating | $2,820,000 | $0 |
| Operating Expense | $251,934,000 | $292,291,000 |
| General And Administrative Expense | $52,124,000 | $63,779,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-219,343,000 | $-274,421,000 |
| Net Interest Income | $4,094,000 | $17,584,000 |
| Interest Income | $6,914,000 | $17,584,000 |
| Normalized Income | $-219,343,000 | $-274,421,000 |
| Net Income From Continuing And Discontinued Operation | $-219,343,000 | $-274,421,000 |
| Total Operating Income As Reported | $-223,469,000 | $-291,973,000 |
| Net Income Common Stockholders | $-219,343,000 | $-281,273,000 |
| Net Income | $-219,343,000 | $-274,421,000 |
| Net Income Including Noncontrolling Interests | $-219,343,000 | $-274,421,000 |
| Net Income Continuous Operations | $-219,343,000 | $-274,421,000 |
| Pretax Income | $-219,343,000 | $-274,421,000 |
| Interest Income Non Operating | $6,914,000 | $17,584,000 |
| Operating Income | $-223,469,000 | $-291,973,000 |
| Depreciation Amortization Depletion Income Statement | $2,693,000 | $2,763,000 |
| Depreciation And Amortization In Income Statement | $2,693,000 | $2,763,000 |
| Gross Profit | $28,465,000 | $318,000 |
| Per Share | ||
| Diluted EPS | - | $-2.65 |
| Basic EPS | - | $-2.65 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-192,167,000 | $-258,554,000 |
| Reconciled Depreciation | $24,356,000 | $15,867,000 |
| EBITDA (Bullshit earnings) | $-192,167,000 | $-258,554,000 |
| EBIT | $-216,523,000 | $-274,421,000 |
| Diluted NI Availto Com Stockholders | $-219,343,000 | $-281,273,000 |
| Otherunder Preferred Stock Dividend | $0 | $6,852,000 |
| Research And Development | $197,117,000 | $225,749,000 |
| Selling General And Administration | $52,124,000 | $63,779,000 |
| Other Gand A | $21,006,000 | $19,291,000 |
| Salaries And Wages | $31,118,000 | $44,488,000 |
| Diluted Average Shares | - | $106,098,869 |
| Basic Average Shares | - | $106,098,869 |
Fetched: 2026-07-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-1,276,949,000 | $-1,069,898,000 |
| Total Assets | $507,053,000 | $551,920,000 |
| Total Non Current Assets | $280,562,000 | $299,317,000 |
| Other Non Current Assets | $13,918,000 | $9,667,000 |
| Goodwill And Other Intangible Assets | $13,813,000 | $14,881,000 |
| Other Intangible Assets | $3,300,000 | $4,368,000 |
| Current Assets | $226,491,000 | $252,603,000 |
| Other Current Assets | $8,520,000 | $7,475,000 |
| Receivables | $1,307,000 | $1,662,000 |
| Accounts Receivable | $1,307,000 | $1,662,000 |
| Cash Cash Equivalents And Short Term Investments | $216,664,000 | $243,466,000 |
| Cash And Cash Equivalents | $78,558,000 | $67,052,000 |
| Debt | ||
| Net Debt | $23,937,000 | - |
| Total Debt | $311,624,000 | $206,516,000 |
| Long Term Debt And Capital Lease Obligation | $301,510,000 | $201,473,000 |
| Long Term Debt | $102,495,000 | - |
| Current Debt And Capital Lease Obligation | $10,114,000 | $5,043,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $1,770,189,000 | $1,606,937,000 |
| Total Non Current Liabilities Net Minority Interest | $1,729,661,000 | $1,565,053,000 |
| Other Non Current Liabilities | $15,433,000 | - |
| Non Current Deferred Liabilities | $49,138,000 | $0 |
| Current Liabilities | $40,528,000 | $41,884,000 |
| Current Deferred Liabilities | $7,123,000 | $0 |
| Payables And Accrued Expenses | $10,783,000 | $25,587,000 |
| Payables | $6,084,000 | $21,012,000 |
| Accounts Payable | $6,084,000 | $21,012,000 |
| Equity | ||
| Common Stock Equity | $-1,263,136,000 | $-1,055,017,000 |
| Total Equity Gross Minority Interest | $-1,263,136,000 | $-1,055,017,000 |
| Stockholders Equity | $-1,263,136,000 | $-1,055,017,000 |
| Gains Losses Not Affecting Retained Earnings | $132,000 | $102,000 |
| Other Equity Adjustments | $132,000 | $102,000 |
| Retained Earnings | $-1,347,105,000 | $-1,127,762,000 |
| Preferred Securities Outside Stock Equity | $1,363,580,000 | $1,363,580,000 |
| Other | ||
| Ordinary Shares Number | $106,098,869 | $106,098,869 |
| Share Issued | $106,098,869 | $106,098,869 |
| Tangible Book Value | $-1,276,949,000 | $-1,069,898,000 |
| Invested Capital | $-1,160,641,000 | $-1,055,017,000 |
| Working Capital | $185,963,000 | $210,719,000 |
| Capital Lease Obligations | $209,129,000 | $206,516,000 |
| Total Capitalization | $-1,160,641,000 | $-1,055,017,000 |
| Treasury Stock | $0 | $2,619,000 |
| Additional Paid In Capital | $83,834,000 | $75,259,000 |
| Capital Stock | $3,000 | $3,000 |
| Common Stock | $3,000 | $3,000 |
| Non Current Deferred Revenue | $49,138,000 | $0 |
| Long Term Capital Lease Obligation | $199,015,000 | $201,473,000 |
| Current Deferred Revenue | $7,123,000 | $0 |
| Current Capital Lease Obligation | $10,114,000 | $5,043,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,508,000 | $11,254,000 |
| Current Accrued Expenses | $4,699,000 | $4,575,000 |
| Goodwill | $10,513,000 | $10,513,000 |
| Net PPE | $252,831,000 | $274,769,000 |
| Accumulated Depreciation | $-50,223,000 | $-29,615,000 |
| Gross PPE | $303,054,000 | $304,384,000 |
| Leases | $147,924,000 | $148,909,000 |
| Construction In Progress | $847,000 | $2,524,000 |
| Other Properties | $97,055,000 | $100,903,000 |
| Machinery Furniture Equipment | $57,228,000 | $52,048,000 |
| Properties | $0 | $0 |
| Other Short Term Investments | $138,106,000 | $176,414,000 |
Fetched: 2026-07-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-131,723,000 | $-256,777,000 |
| Operating Activities | ||
| Operating Cash Flow | $-110,669,000 | $-196,367,000 |
| Cash Flow From Continuing Operating Activities | $-110,669,000 | $-196,367,000 |
| Operating Gains Losses | $204,000 | $863,000 |
| Investing Activities | ||
| Capital Expenditure | $-21,054,000 | $-60,410,000 |
| Investing Cash Flow | $21,383,000 | $-52,810,000 |
| Cash Flow From Continuing Investing Activities | $21,383,000 | $-52,810,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $0 | $263,963,000 |
| Financing Cash Flow | $100,761,000 | $263,992,000 |
| Cash Flow From Continuing Financing Activities | $100,761,000 | $263,992,000 |
| Net Other Financing Charges | $-1,355,000 | $-308,000 |
| Net Preferred Stock Issuance | $0 | $263,963,000 |
| Preferred Stock Issuance | $0 | $263,963,000 |
| Other | ||
| Repayment Of Debt | $-159,000 | $-256,000 |
| Issuance Of Debt | $101,636,000 | $0 |
| Interest Paid Supplemental Data | $0 | $20,000 |
| End Cash Position | $87,676,000 | $76,170,000 |
| Beginning Cash Position | $76,170,000 | $61,309,000 |
| Effect Of Exchange Rate Changes | $31,000 | $46,000 |
| Changes In Cash | $11,475,000 | $14,815,000 |
| Proceeds From Stock Option Exercised | $639,000 | $593,000 |
| Net Issuance Payments Of Debt | $101,477,000 | $-256,000 |
| Net Long Term Debt Issuance | $101,477,000 | $-256,000 |
| Long Term Debt Payments | $-159,000 | $-256,000 |
| Long Term Debt Issuance | $101,636,000 | $0 |
| Net Investment Purchase And Sale | $42,437,000 | $7,435,000 |
| Sale Of Investment | $299,000,000 | $444,000,000 |
| Purchase Of Investment | $-256,563,000 | $-436,565,000 |
| Net Business Purchase And Sale | $0 | $165,000 |
| Sale Of Business | $0 | $165,000 |
| Net PPE Purchase And Sale | $-21,054,000 | $-60,410,000 |
| Purchase Of PPE | $-21,054,000 | $-60,410,000 |
| Change In Working Capital | $72,292,000 | $39,706,000 |
| Change In Other Working Capital | $56,261,000 | - |
| Change In Other Current Liabilities | $17,733,000 | $35,214,000 |
| Change In Other Current Assets | $269,000 | $-37,000 |
| Change In Payables And Accrued Expense | $-1,281,000 | $-2,665,000 |
| Change In Accrued Expense | $1,052,000 | $-13,382,000 |
| Change In Payable | $-2,333,000 | $10,717,000 |
| Change In Account Payable | $-2,333,000 | $10,717,000 |
| Change In Prepaid Assets | $-1,045,000 | $4,891,000 |
| Change In Receivables | $355,000 | $2,303,000 |
| Changes In Account Receivables | $355,000 | $2,303,000 |
| Other Non Cash Items | $5,397,000 | $10,278,000 |
| Stock Based Compensation | $10,555,000 | $19,282,000 |
| Amortization Of Securities | $-4,130,000 | $-7,942,000 |
| Depreciation Amortization Depletion | $24,356,000 | $15,867,000 |
| Depreciation And Amortization | $24,356,000 | $15,867,000 |
| Gain Loss On Sale Of PPE | $204,000 | $863,000 |
| Net Income From Continuing Operations | $-219,343,000 | $-274,421,000 |
Fetched: 2026-07-22